natgillin/translations-raw huggingface dataset:
Therapy should usually not be resumed earlier than 48 hours following surgery and only after renal function has been reevaluated and found to be normal.
Zdravljenje z zdravilom se navadno ne sme ponovno uvesti prej kot 48 ur po kirurškem posegu in šele po ponovni oceni delovanja ledvic, če je izvid normalen.
Empagliflozin is a reversible, highly potent (IC50 of 1.3 nmol) and selective competitive inhibitor of SGLT2.
Empagliflozin je reverzibilen, izjemno močan (IC50 1,3 nmol) in selektiven kompetitiven zaviralec
You should stop taking Synjardy at least 48 hours before planned surgery with general, spinal or peridural anaesthesia and should not start again until at least 48 hours afterwards.
Zdravilo Synjardy boste morali prenehati jemati vsaj 48 ur pred načrtovano operacijo v splošni, spinalni ali epiduralni anesteziji, zdravljenje pa smete znova nadaljevati najmanj 48 ur po posegu.
• if you need to have an injection of contrast agent that contains iodine, for example before an X-ray or scan.
• če morate prejeti injekcijo jodiranega kontrastnega sredstva, npr. pred rentgenskim ali drugačnim slikanjem.
Synjardy should not be used in patients with type 1 diabetes.
Zdravila Synjardy ne smejo uporabljati bolniki s sladkorno boleznijo tipa 1.
Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/l, and an increased anion gap and lactate/pyruvate ratio.
Diagnostični laboratorijski izvidi kažejo znižano pH-vrednost krvi, raven laktatov v plazmi nad 5 mmol/l ter povečano anionsko vrzel in razmerje laktati/piruvat.
Metformin The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in type 2 diabetes.
V prospektivni randomizirani študiji (UKDPS) je bila dokazana dolgoročna korist intenzivnega urejanja glukoze v krvi pri sladkorni bolezni tipa 2.
Difference from placebo1
Razlika glede na placebo1
Other medicines and Synjardy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Metformin, one of the active substances in this medicine, can cause a very rare (may affect up to 1 in 10,000 people) but serious side effect called ‘lactic acidosis'.
Metformin, ena od zdravilnih učinkovin tega zdravila, lahko povzroči zelo redek (pojavi se lahko pri največ 1 od 10.000 bolnikov), a resen neželeni učinek “laktacidozo”.
Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 6).
Zdravljenje z empagliflozinom enkrat na dan je povzročilo statistično značilno izboljšanje HbA1c in 24-urnega povprečnega sistoličnega in diastoličnega krvnega tlaka, kot je bilo ugotovljeno z ambulantnim spremljanjem krvnega tlaka (preglednica 6).
• Diabetic ketoacidosis, diabetic pre-coma.
• Diabetična ketoacidoza, diabetična predkoma.
ketoacidosisa, b Lactic acidosis3
ketoacidozaa, b laktacidoza pomanjkanje vitamina
Of these, a total of 530 patients received empagliflozin as add-on to metformin plus insulin, of which 266 patients were treated with empagliflozin 10 mg and 264 with empagliflozin 25 mg.
Od teh je skupno 530 bolnikov prejemalo empagliflozin kot dodatno zdravljenje k metforminu in insulinu, od teh pa je bilo 266 bolnikov zdravljenih z empagliflozinom 10 mg in 264 z empagliflozinom 25 mg.
5 Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.
5 Prebavni simptomi, kot so slabost, bruhanje, driska, trebušne bolečine in zmanjšan tek, se najpogosteje pojavljajo na začetku zdravljenja ter večinoma spontano minejo.
Following administration of an oral [14C]-empagliflozin solution to healthy volunteers, approximately 96% of the drug-related radioactivity was eliminated in faeces (41%) or urine (54%).
[14C]-empagliflozina se je pri zdravih prostovoljcih približno 96 % radioaktivnosti, povezane z zdravilom, izločilo v blato (41 %) ali urin (54 %).
The majority of drug-related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug.
Večina radioaktivnosti v blatu, povezane z zdravilom je bila nespremenjena izhodna učinkovina in približno polovica radioaktivnosti v urinu,
The frequency of patients with hypoglycaemic events was similar for empagliflozin and placebo as add-on to metformin.
Pogostnost bolnikov s hipoglikemičnimi dogodki je bila podobna za empagliflozin in placebo kot dodatno zdravljenje k metforminu.
Lactic acidosis is characterised by acidotic dyspnea, abdominal pain and hypothermia followed by coma.
Za laktacidozo so značilni acidozna dispneja, trebušne bolečine in hipotermija, ki ji sledi koma.
Hypoglycaemia (when used with sulphonylurea or insulin)1
Presnovne in prehranske motnje hipoglikemija (pri uporabi s sulfonilsečnino ali insulinom)1
Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection1, 2
Infekcijske in parazitske bolezni vaginalna kandidoza, vulvovaginitis, balanitis in druge okužbe spolovil1,
Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with renal failure or acute worsening of renal function.
Primeri laktacidoze, o katerih so poročali pri bolnikih, ki jemljejo metformin, so se pojavili zlasti pri sladkornih bolnikih z okvaro ledvic ali akutnim poslabšanjem delovanja ledvic.
These may be medicines taken by mouth or insulin given by injection.
To so lahko zdravila, ki se jemljejo peroralno (se zaužijejo) ali pa je to insulin, ki se injicira.
Difference from glimepiride1 (97.5% CI)
Razlika glede na glimepirid1 (97,5-odstotni
Gastrointestinal symptoms3, 5
Bolezni prebavil prebavni simptomi3, 5
• if you have uncontrolled diabetes, with e.g. severe hyperglycaemia (high blood glucose), nausea, vomiting, dehydration, rapid weight loss or ketoacidosis.
• če imate nekontrolirano sladkorno bolezen s hudo hiperglikemijo (povišan krvni sladkor), slabostjo, bruhanjem, dehidracijo, hitro izgubo telesne mase ali ketoacidozo.
Do not stop taking Synjardy without first consulting your doctor.
Če ste prenehali jemati zdravilo Synjardy Ne prenehajte jemati zdravila Synjardy, ne da bi se prej posvetovali z zdravnikom.
Your doctor may ask you to stop taking Synjardy until you have recovered;
Vaš zdravnik vam bo morda naročil, da zdravilo Synjardy prenehate jemati, dokler ne okrevate;
There is an increased risk of lactic acidosis following excessive alcohol consumption (particularly in the case of fasting, malnutrition, or liver disease).
Nevarnost laktacidoze je povečana pri prekomernem uživanju alkohola (zlasti ob postu, podhranjenosti ali jetrni okvari).
Liver function tests abnormalities3 Hepatitis3
žolčnika in žolčevodov nenormalni izvidi testov jetrnih funkcij3 hepatitis3
• if you drink alcohol to excess, either every day or only from time to time (see section “Synjardy with alcohol”).
• če imate težave z jetri; • če vsak dan ali samo občasno pijete prevelike količine alkohola (glejte poglavje “Zdravilo
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 4).
Takoj prenehajte jemati to zdravilo in se obrnite na zdravnika ali takoj pojdite v bolnišnico (glejte poglavje 4).
Due to its mechanism of action, patients taking Synjardy will test positive for glucose in their urine.
Zaradi mehanizma delovanja bodo rezultati testov glukoze v urinu pri bolnikih, ki jemljejo zdravilo Synjardy, pozitivni.
There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic impairment due to the metformin active substance (see section 4.4)).
Nevarnost laktacidoze je povečana pri akutni zastrupitvi z alkoholom (zlasti ob postu, podhranjenosti ali jetrni okvari, zaradi zdravilne učinkovine metformina (glejte poglavje 4.4)).
1 See subsections below for additional information
1 Za dodatne informacije glejte spodnja podpoglavja.
Complicated urinary tract infection (e.g. pyelonephritis or urosepsis) occurred at a similar frequency in patients treated with empagliflozin compared to placebo.
Zapletene okužbe sečil (npr. pielonefritis ali urosepsa) so se pri bolnikih, zdravljenih z empagliflozinom, pojavile s podobno pogostnostjo kot pri placebu.
Biotransformation Metformin is excreted unchanged in the urine.
Metformin se nespremenjen izloči z urinom.
Table 1 Adverse reactions reported in placebo-controlled studies System organ class
Preglednica 1: Neželeni učinki, o katerih so poročali v s placebom nadzorovanih študijah
The European Medicines Agency has waived the obligation to submit the results of studies with Synjardy in all subsets of the paediatric population in type 2 diabetes (see section 4.2 for information on paediatric use).
Synjardy za vse podskupine pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Dysuria2
disurija2
The risk of developing lactic acidosis is also increased with uncontrolled diabetes, prolonged fasting or alcohol intake, body fluid deficit (dehydration) due to severe diarrhoea or vomiting, liver problems and any medical conditions in which a region of the body is deprived with a lack of oxygen supply (such as acute severe heart diseases).
Tveganje za nastanek laktacidoze je povečano tudi ob nenadzorovani sladkorni bolezni, dolgotrajnejšem postu ali uživanju alkohola, pomanjkanju telesnih tekočin (dehidracija) zaradi hude driske ali bruhanja, težavah z jetri in vsakem stanju, pri katerem ima del telesa pomanjkljivo oskrbo s kisikom (kot so akutna in huda obolenja srca).
Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with empagliflozin in NYHA class III-IV.
Heart Association) so omejene, izkušenj iz kliničnih študij z empagliflozinom z razredom III-IV po
At Week 18, empagliflozin provided statistically significant improvement in HbA1c compared with placebo (Table 4).
V 18. tednu je pri empagliflozinu prišlo do statistično značilnega izboljšanja vrednosti HbA1c v primerjavi s placebom (preglednica 4).
Symptoms include rapid weight loss, feeling sick or being sick, stomach pain, fast and deep breathing, sleepiness or unusual fruity odour of the breath;
Simptomi vključujejo hitro izgubo telesne mase, občutek slabosti ali bruhanje, trebušne bolečine, hitro in globoko dihanje, zaspanost ali nenavaden saden zadah.
Other associated risk factors should be considered to avoid lactic acidosis such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any condition associated with hypoxia (such as decompensated cardiac failure, acute myocardial infarction) (see section 4.3).
Da bi preprečili pojav laktacidoze, je treba upoštevati tudi druge povezane dejavnike tveganja, kot so slabo nadzorovana sladkorna bolezen, ketoza, dolgotrajnejši post, čezmerno uživanje alkohola, jetrna okvara in vsako stanje, ki je povezano s hipoksijo (kot je dekompenzirano srčno popuščanje, akutni miokardni infarkt) (glejte poglavje 4.3).
Stop taking Synjardy immediately and contact a doctor or the nearest hospital straight away.
Takoj prenehajte jemati zdravilo Synjardy in se nemudoma posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
If this happens to you, you may need immediate hospital treatment, as lactic acidosis may lead to coma.
Če se pri vas pojavijo ti simptomi, boste morda potrebovali takojšnje bolnišnično zdravljenje, saj lahko laktacidoza vodi v komo.
If you experience some of these symptoms, you should seek immediately medical attention, as lactic acidosis may lead to coma.
Če opazite katerega izmed teh simptomov, nemudoma pokličite zdravnika, saj lahko laktacidoza vodi v komo.
Hypoglycaemia The frequency of hypoglycaemia depended on the background therapy in the respective studies.
Hipoglikemija Pogostnost hipoglikemije je bila odvisna od sočasno uporabljenih zdravil v zadevnih študijah.
The efficacy and safety of empagliflozin as add on to basal insulin with concomitant metformin therapy was evaluated in a double-blind, placebo-controlled trial of 78 weeks duration.
Učinkovitost in varnost empagliflozina kot dodatnega zdravljenja k bazalnemu insulinu s sočasnim metforminom so ocenili v dvojno slepem, s placebom nadzorovanem 78-tedenskem preskušanju.
Empagliflozin as add-on to metformin, sulphonylurea, pioglitazone Empagliflozin as add-on to metformin, metformin and a sulphonylurea, or pioglitazone and metformin resulted in statistically significant (p<0.0001) reductions in HbA1c and body weight compared to placebo (Table 2).
Empagliflozin kot dodatno zdravljenje k metforminu, sulfonilsečnini, pioglitazonu Empagliflozin kot dodatno zdravljenje k metforminu, metforminu s sulfonilsečnino ali pioglitazonu z metforminom je povzročilo statistično značilno (p < 0,0001) zmanjšanje vrednosti HbA1c in telesne mase v primerjavi s placebom (preglednica 2).
Therefore, avoid consumption of alcohol and medicines containing alcohol when taking Synjardy (see section 4, ‘Possible side effects').
Če jemljete zdravilo Synjardy, ne uživajte alkohola in ne uporabljajte zdravil, ki ga vsebujejo (glejte poglavje 4 “Možni neželeni učinki”).
(95% CI) a Full analysis set (FAS)
Razlika glede na placebo5 (95-odstotni IZ) a Niz celotne analize (FAS, full analysis set)
• difficulty breathing
• huda utrujenost • težave z dihanjem
The intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.
Intravaskularno dajanje jodiranih kontrastnih sredstev v radioloških študijah lahko pripelje do ledvične odpovedi, ki povzroči kopičenje metformina in s tem tveganje za pojav laktacidoze.
Placebo
za placebo.
Special caution should be paid to situations where renal function may become impaired, for example in case of dehydration (severe diarrhoea or vomiting), or when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).
Posebna previdnost je potrebna v razmerah, v katerih bi se lahko delovanje ledvic poslabšalo, na primer ob dehidraciji (huda driska ali bruhanje) ali ob začetku zdravljenja z antihipertenzivom, diuretikom ali nesteroidnim protivnetnim zdravilom (NSAID).
For patients inadequately controlled on metformin monotherapy or metformin in combination with other glucose-lowering medicinal products including insulin In patients not adequately controlled on metformin alone or in combination with other glucose-lowering medicinal products, including insulin, the recommended starting dose of Synjardy should provide empagliflozin 5 mg twice daily (10 mg daily dose) and the dose of metformin similar to the dose already being taken.
Pri bolnikih z nezadostno urejeno boleznijo pri jemanju metformina v monoterapiji ali v kombinaciji z drugimi zdravili, ki nižajo raven glukoze, vključno z insulinom Priporočeni začetni odmerek zdravila Synjardy pri bolnikih z nezadostno urejeno boleznijo pri jemanju metformina v monoterapiji ali v kombinaciji z drugimi zdravili, ki nižajo raven glukoze, vključno z insulinom, je 5 mg empagliflozina dvakrat dnevno (dnevni odmerek je 10 mg) s podobnim odmerkom metformina, kot so ga že jemali.
The following statements reflect the pharmacokinetic properties of the individual active substances of Synjardy.
Spodnje trditve temeljijo na farmakokinetičnih lastnostih posameznih zdravilnih učinkovin zdravila
SGLT2 prevents glucose (blood sugar) from being lost in urine by absorbing glucose back into the bloodstream as blood is being filtered in the kidneys.
(krvnega sladkorja) v urinu, tako da absorbira glukozo nazaj v krvni obtok, medtem ko se kri filtrira v ledvicah.
In this analysis, AUC was estimated to be 5.82%, 10.4%, and 17.3% lower in subjects with BMI of 30, 35, and 45 kg/m2, respectively, compared to subjects with a body mass index of 25 kg/m2.
10,4 % oz. 17,3 % nižja pri osebah z ITM 30, 35 oz. 45 kg/m2 v primerjavi z osebami z indeksom telesne mase 25 kg/m2.
An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of empagliflozin and metformin at exposures of approximately 14-times the clinical AUC exposure of empagliflozin associated with the highest dose, and 4-times the clinical AUC exposure of metformin associated with the 2000 mg dose.
Študija o učinkih na razvoj zarodka in plodu pri brejih podganah ni pokazala teratogenih učinkov sočasnega dajanja empagliflozina in metformina pri izpostavljenostih, ki so bile približno 14-krat večje od klinične izpostavljenosti empagliflozinu na podlagi vrednosti AUC, ki je povezana z največjim odmerkom, in 4-krat večje od klinične izpostavljenosti metforminu na podlagi vrednosti
In vitro studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.
Podatki in vitro kažejo, da je glavna presnovna pot empagliflozina pri ljudeh glukuronidacija z uridin 5‘-difosfo-glukuronoziltransferazami UGT1A3, UGT1A8, UGT1A9 in UGT2B7.
Due to the metformin component, co-administration of anaesthesia can increase the risk of side effects.
Zaradi metformina lahko sočasno dajanje anestezije poveča tveganje neželenih učinkov.
Metformin is excreted into human milk.
Dojenje Metformin se izloča v materino mleko.
Table 6 Efficacy results at 12 week in a placebo-controlled study of empagliflozin in patients with type 2 diabetes and uncontrolled blood pressurea
Preglednica 6: Rezultati učinkovitosti v 12. tednu v s placebom nadzorovani študiji empagliflozina pri bolnikih s sladkorno boleznijo tipa 2 in nekontroliranim krvnim tlakoma placebo empagliflozin
In a prospective, pre-specified meta-analysis of independently adjudicated cardiovascular events from 12 phase 2 and 3 clinical studies involving 10,036 patients with type 2 diabetes, empagliflozin did not increase cardiovascular risk.
12 kliničnih študijah 2. in 3. faze, ki so zajele 10.036 bolnikov s sladkorno boleznijo tipa 2,
2 Identified adverse reactions of empagliflozin monotherapy 3 Identified adverse reactions of metformin monotherapy 4 Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia)
4 Dolgotrajno zdravljenje z metforminom so povezali z zmanjšano absorpcijo vitamina B12, kar lahko zelo redko pripelje do klinično pomembnega pomanjkanja tega vitamina (npr. megaloblastne anemije).
Empagliflozin 24 months data, as add-on to metformin in comparison to glimepiride In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (up to 4 mg per day) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c (Table 3), and a clinically meaningful reduction in FPG, compared to glimepiride.
V študiji, v kateri so primerjali učinkovitost in varnost empagliflozina 25 mg z glimepiridom (do 4 mg na dan) pri bolnikih z neustrezno urejeno glikemijo, ki so dobivali samo metformin, je dnevno zdravljenje z empagliflozinom povzročilo večje zmanjšanje vrednosti HbA1c (preglednica 3), in klinično pomembno zmanjšanje vrednosti FPG, v primerjavi z gimepiridom.
A total of 4704 patients with type 2 diabetes were treated in 7 double-blind, placebo or active-controlled clinical studies of at least 24 weeks duration, of which 1109 patients received empagliflozin 10 mg and 1863 received empagliflozin 25 mg as add-on to metformin therapy.
Klinična učinkovitost in varnost V 7 dvojno slepih, s placebom ali zdravilno učinkovino nadzorovanih kliničnih študijah, je bilo zdravljenih skupaj 4.704 bolnikov s sladkorno boleznijo tipa 2 najmanj 24 tednov, od tega jih je 1.109 prejemalo empagliflozin 10 mg in 1.863 empagliflozin 25 mg kot dodatno zdravljenje k metforminu.
Table 4: Efficacy results at 18 and 52 weeks in a placebo-controlled study of empagliflozin as add-on to multiple daily doses of insulin with concomitant metformin therapy
Preglednica 4: Rezultati učinkovitosti v 18. in 52. tednu v s placebom nadzorovani študiji z empagliflozinom kot dodatnim zdravljenjem k večkratnim dnevnim odmerkom insulina sočasno z metforminom placebo empagliflozin
A greater proportion of patients treated with empagliflozin and with a baseline HbA1c ≥7.0% achieved a target HbA1c of <7% compared to placebo (Table 5).
V primerjavi s placebom je večji delež bolnikov, zdravljenih z empagliflozinom in z izhodiščno vrednostjo HbA1c ≥ 7,0 %, dosegel ciljno vrednost HbA1c < 7 % (preglednica 5).
Special caution should be exercised in situations where renal function may become impaired, for example in case of dehydration, or when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).
Posebna previdnost je potrebna v razmerah, ko bi lahko prišlo do okvare v delovanju ledvic, na primer v primeru dehidracije ali na začetku zdravljenja z antihipertenzivom, diuretikom ali nesteroidnim protivnetnim zdravilom
An urge to pass urine or more frequent urination may be due to the way Synjardy works, but as they can also be signs of urinary tract infection.
• bolečina v predelu medenice ali sredine hrbta (če so okužene ledvice) Nuja po uriniranju ali pogostejše uriniranje sta lahko posledica načina delovanja zdravila Synjardy, vendar sta lahko tudi znak okužbe sečil, zato se morate z zdravnikom posvetovati tudi, če se število teh simptomov poveča.
• feeling sick (nausea), vomiting
Zelo pogosti • občutek slabosti (navzea), bruhanje
A total of 7052 patients with type 2 diabetes were treated in clinical studies to evaluate the safety of empagliflozin as add-on to metformin, of which 4740 patients were treated with empagliflozin as add-on to metformin.
V klinične študije za ocenitev varnosti empagliflozina kot dodatnega zdravljenja k metforminu je bilo vključenih skupaj 7.052 bolnikov s sladkorno boleznijo tipa 2, od katerih se je 4.740 zdravilo z empagliflozinom kot dodatnim zdravljenjem k metforminu.
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away.
Takoj prenehajte jemati to zdravilo in se obrnite na zdravnika ali takoj pojdite v bolnišnico.
* p-value <0.0001 ** p-value <0.01
* vrednost p < 0,0001 ** vrednost p < 0,001
The overall frequency of urinary tract infection reported as adverse event was higher in patients treated with empagliflozin 10 mg on a background of metformin compared to patients treated with placebo or empagliflozin 25 mg on a background of metformin (see section 4.8).
Skupna pogostnost okužb sečil, o kateri so poročali kot o neželenem učinku, je bila pri bolnikih, zdravljenih z empagliflozinom 10 mg, večja v primerjavi z bolniki, ki so prejemali placebo ali empagliflozin 25 mg, pri čemer sta obe skupini zdravila prejemali skupaj z metforminom (glejte poglavje 4.8).
The risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps, digestive disorders as abdominal pain and severe asthenia.
Na možnost laktacidoze je treba premisliti, če se pojavijo nespecifični znaki, kot so mišični krči, prebavne motnje, kot so trebušne bolečine, in huda astenija.
Table 2: Efficacy results of 24 week placebo-controlled studies Add-on to metformin therapya
Preglednica 2: Rezultati učinkovitosti 24-tedenskih s placebom nadzorovanih študij Dodatno zdravljenje k metforminua placebo empagliflozin